相关实验视频

Updated: Jul 11, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

临床病理学特征与先进的肺腺癌中的编程细胞死亡-干1表达相关

Hengxing Gao¹, Xuexue Zou², Jing Wang³

¹Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Journal of thoracic disease

|November 16, 2023

概括

使用常见的临床病理特征,可以预测晚期肺腺癌中编程细胞死亡配体1 (PD-L1) 表达的情况. 血清CEA,NSE,T阶段和WBC可以帮助预测PD-L1水平用于免疫检查点抑制剂 (ICI) 疗效评估.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
生物标志物研究生物标志物研究

背景情况:

针对编程细胞死亡连接体1 (PD-L1) 的免疫检查点抑制剂 (ICI) 在非小细胞肺癌 (NSCLC) 中表现有前途.
肺腺癌 (ADC) 中与PD-L1表达相关的临床病理学特征需要进一步阐明.
了解PD-L1表达预测因子对于优化ICI治疗至关重要.

研究的目的:

在晚期肺腺癌 (ADC) 瘤组织中确定编程细胞死亡配体1 (PD-L1) 表达水平.
分析PD-L1表达和各种临床病理学特征之间的关系.
为了确定PD-L1表达在晚期肺部ADC的可靠预测剂.

主要方法:

对136名晚期肺部ADC患者的回顾性分析,具有PD-L1数据.
免疫组织化学用于评估瘤组织中的PD-L1表达,对阳性/阴性分类的截止值为1%.
PD-L1水平与临床病理特征之间的相关性分析,包括后勤回归和ROC曲线分析.

主要成果:

与性别相关的PD-L1表达,临床阶段,血清CEA,NSE,WBC和T/M阶段.
血清CEA,NSE,T阶段和WBC被确定为积极PD-L1表达的独立预测因素.
一个CEA和NSE的组合模型显示了PD-L1水平的强有力的预测性能 (AUC = 0.815).

结论:

常见的临床病理特征,包括血清CEA,NSE,T阶段和WBC,与晚期肺部ADC的PD-L1表达有关.
这些特征可以作为PD-L1表达水平的预测指标.
使用这些标记物预测PD-L1状态可能有助于在治疗前评估免疫检查点抑制剂 (ICI) 的潜在疗效.

关键词:

癌胚抗原 (CEA) 是一种癌胚抗原.神经元特异性酶 (NSE) 是一种神经元特异性酶.预测器预测器预测器瘤结节转移 (TNM阶段)白血细胞 (WBC) 是一种

更多相关视频

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...